Description of Procedure or Service
Rituximab is a chimeric murine-human monoclonal antibody directed against the CD20 surface antigen, which is expressed on pre-B and mature B lymphocytes. Rituximab induces lysis of normal and malignant CD20-expressing B cells; possible mechanisms of cell lysis include complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. B cells are thought to play a role in the pathogenesis of rheumatoid arthritis and other autoimmune diseases by producing autoantibodies and proinflammatory cytokines and by activating T lymphocytes. Rituximab reduces the number of B cells in the peripheral blood and in lymphoid tissues, thereby interrupting pathogenic processes of autoimmune diseases. Rituximab is administered by intravenous infusion. 
Policy
BCBSNC will provide coverage for rituximab (Rituxan ® ) for the treatment of rheumatoid arthritis when it is determined to be medically necessary because the medical criteria and guidelines shown below are met.
Benefits Application
This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.
Rituximab may be subject to prior review requirements.
When Rituximab for the Treatment of Rheumatoid Arthritis is covered
Rituximab (Rituxan ® ) for the treatment of adults with rheumatoid arthritis may be considered medically necessary under the following conditions:
1. The patient has moderately to severely active rheumatoid arthritis; AND 2. Rituximab is administered in combination with methotrexate (unless contraindicated); 
When Rituximab for the Treatment of Rheumatoid Arthritis is not covered
1. Rituximab for the treatment of rheumatoid arthritis is considered not medically necessary when the criteria stated above are not met.
2. Rituxan ® is considered not medically necessary when used in combination with TNFinhibiting drugs.
Policy Guidelines
The U.S. Food and Drug Administration has approved rituximab for individuals who have moderately to severely active rheumatoid arthritis and inadequate response to one or more standard agent (e.g., tumor necrosis factor inhibitors, methotrexate or other conventional synthetic disease-modifying anti-rheumatic drugs), and who receive rituximab and methotrexate. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome. Rituximab should be administered by a healthcare professional with appropriate medical support to manage severe and potentially fatal infusion reactions.
Rituximab carries the following black box warnings:
• Fatal infusion reactions within 24 hours of rituximab infusion; approximately 80% of fatal reactions occurred with first infusion.
• Severe mucocutaneous reactions, some with fatal outcomes.
• Hepatitis B virus reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death.
• Progressive multifocal leukoencephalopathy resulting in death.
Labeled warnings and precautions include:
• Tumor lysis syndrome (for patients with hematologic malignancies)
• Infections • Cardiac arrhythmias and angina • Bowel obstruction and perforation • Live virus vaccines: Do not administer live virus vaccines before or during rituximab therapy • Cytopenias Rituximab is pregnancy category C: There are no adequate and well-controlled studies for rituximab during pregnancy. Individuals of childbearing potential should use effective contraception while receiving rituximab and for 12 months after treatment. Rituximab may be used during pregnancy only if potential benefit justifies potential risks to the fetus.
Billing/Coding/Physician Documentation Information
This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page. M05.672, M05.679, M05.69, M06.9, M06.80, M06.811, M06.812, M06.819, M06.821, M06.822, M06.829, M06.831, M06.832, M06.839, M06.841, M06.842, M06.849, M06.851, M06.852, M06.859, M06.861, M06.862, M06.869, M06.871, M06.872, M06.879, M06.88, M06.89,M08.00, M08.09, M08.29, M08.011, M08.012, M08.019, M08.021, M08.022, M08.029, M08.031, M08.032, M08.039, M08.041, M08.042, M08.049, M08.051, M08.052, M08.059, M08.061, M08.062, M08.069, M08.071, M08.072, M08.079, M08.08, M08.20, M08.211, M08.212, M08.219, M08.221, M08.222, M08.229, M08.231, M08.232, M08.239, M08.241, M08.242, M08.249, M08.251, M08.252, M08.259, M08.261, M08.262, M08.269, M08.271, M08.272, M08.279, M08.28, M08.29, M08.00, M08.011, M08.012, M08.019, M08.021, M08.022, M08.029, M08.031, M08.032, M08.039, M08.041, M08.042, M08.049, M08.051, M08.052, M08.059, M08.061, M08.062, M08.069, M08.071, M08.072, M08.079, M08.09, M08.40, M08.411, M08.412, M08.419, M08.421, M08.422, M08.429, M08.431, M08.432, M08.439, M08.441, M08.442, M08.449, M08.451, M08.452, M08.459, M08.461, M08.462, M08.469, M08.471, M08.472, M08.479, M08.48, M12.00, M12.011, M12.012, M12.019, M12.021, M12.022, M12.029, M12.031, M12.032, M12.039, M12.041, M12.042, M12.049, M12.051, M12.052, M12.059, M12.061, M12.062, M12.069, M12.071, M12.072, M12.079, M12.08, M12.09, M06.4, M45.0, M45.1, M45.2, M45.3, M45.4, M45.5, M45.6, M45.7, M45.8, M45.9 Medical 
